Positron Emission Tomography Using [18F]Galacto-RGD Identifies the Level of Integrin αvβ3 Expression in Man

• Published in: Clinical cancer research 2006-07, Vol.12 (13), p.3942-3949
• Main Authors: Beer, Ambros J., Haubner, Roland, Sarbia, Mario, Goebel, Michael, Luderschmidt, Stephan, Grosu, Anca Ligia, Schnell, Oliver, Niemeyer, Markus, Kessler, Horst, Wester, Hans-Jürgen, Weber, Wolfgang A., Schwaiger, Markus
• Format: Article
• Language: English
• Subjects: angiogenesis and microcirculation; angiogenic factors and receptors; cell-matrix interactions; diagnostic imaging; PET scans
• ISSN: 1078-0432; 1557-3265
• DOI: 10.1158/1078-0432.CCR-06-0266

Purpose: The integrin α v β 3 plays a key role in angiogenesis and tumor cell metastasis and is therefore an important target for new therapeutic and diagnostic strategies. We have developed [ 18 F]Galacto-RGD, a highly α v β 3 -selective tracer for positron emission tomography (PET). Here, we show, in man, that the intensity of [ 18 F]Galacto-RGD uptake correlates with α v β 3 expression. Experimental Design: Nineteen patients with solid tumors (musculoskeletal system, n = 10; melanoma, n = 4; head and neck cancer, n = 2; gliobastoma, n = 2; and breast cancer, n = 1) were examined with PET using [ 18 F]Galacto-RGD before surgical removal of the tumor lesions. Snap-frozen specimens ( n = 26) were collected from representative areas with low and intense standardized uptake values (SUV) of [ 18 F]Galacto-RGD. Immunohistochemistry was done using the α v β 3 -specific antibody LM609. Intensity of staining (graded on a four-point scale) and the microvessel density of α v β 3 -positive vessels were determined and correlated with SUV and tumor/blood ratios (T/B). Results: Two tumors showed no tracer uptake (mean SUV, 0.5 ± 0.1). All other tumors showed tracer accumulation with SUVs ranging from 1.2 to 10.0 (mean, 3.8 ± 2.3; T/B, 3.4 ± 2.2; tumor/muscle ratio, 7.7 ± 5.4). The correlation of SUV and T/B with the intensity of immunohistochemical staining (Spearman's r = 0.92; P < 0.0001) as well as with the microvessel density (Spearman's r = 0.84; P < 0.0001) were significant. Immunohistochemistry confirmed lack of α v β 3 expression in normal tissue (benign lymph nodes, muscle) and in the two tumors without tracer uptake. Conclusions: Molecular imaging of α v β 3 expression with [ 18 F]Galacto-RGD in humans correlates with α v β 3 expression as determined by immunohistochemistry. PET with [ 18 F]Galacto-RGD might therefore be used as a new marker of angiogenesis and for individualized planning of therapeutic strategies with α v β 3 -targeted drugs.